Biography
Marco Infante obtained his M.D. degree with honors at Sapienza University of Rome in 2014. In 2019, he received the Board Certification in Endocrinology and Metabolic Disorders, with honors, at the University of Rome Tor Vergata. In 2023, he obtained the Ph.D. degree in Systems and Experimental Medicine (European Ph.D. Label) at the University of Rome Tor Vergata, with the final evaluation of “Excellent quality, with honors”. In 2019, he joined the Clinical Cell Transplant Program (CCTP) at the Diabetes Research Institute (DRI) of the University of Miami Miller School of Medicine (Miami, FL, USA) as a Research Scholar. In 2024, he was appointed Affiliate Associate Professor at the Diabetes Research Institute (DRI) of the University of Miami Miller School of Medicine (DRI Cell Transplant Center, Division of Cellular Transplantation, Department of Surgery – University of Miami Miller School of Medicine), where he has been conducting clinical research in the field of pancreatic islet transplantation, diabetes technology and immunotherapies for the treatment of type 1 diabetes mellitus. Since 2025, he has been holding the position of Associate Professor of Endocrinology at UniCamillus – Saint Camillus International University of Health Sciences (Faculty of Medicine and Surgery; Rome – Venice, Italy). In 2020, he was appointed Distinguished Supervisor for the international Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA) of the Universal Scientific Education and Research Network (USERN). In 2021, Marco Infante received the designation as Fellow of the American College of Nutrition (FACN) by virtue of his research activity in the field of “Immunomodulatory Nutrition”. In recognition of his significant scientific contributions to the field of diabetes mellitus, in August 2023 Marco Infante has been inducted, as a Full Member, into the Sigma Xi Scientific Research Honor Society, the world’s largest interdisciplinary scientific honor society founded in 1886 at Cornell University (Ithaca, NY, USA). Moreover, he is currently serving as Associate Editor and Academic Editor of the international peer-reviewed journals “Frontiers in Clinical Diabetes and Healthcare” and “Journal of Diabetes Research” (Wiley publisher), respectively. In May 2024, the USCIS (U.S. Citizenship and Immigration Services) granted Marco Infante the U.S. Extraordinary Ability O1 Visa for Extraordinary Ability in the Sciences.
UniCamillus
Marco Infante serves as Associate Professor of Endocrinology at UniCamillus – Saint Camillus International University of Health Sciences (Faculty of Medicine and Surgery; Rome – Venice, Italy).
Diabetes Research Institute Federation (DRIF)
Marco Infante serves as Affiliate Associate Professor at the Diabetes Research Institute (DRI) of the University of Miami Miller School of Medicine (DRI Cell Transplant Center, Division of Cellular Transplantation, Department of Surgery – University of Miami Miller School of Medicine). Marco Infante is also a member of several national and international scientific organizations and societies, including the American Diabetes Association (ADA), the American Nutrition Association (ANA), the International Pancreas and Islet Transplant Association (IPITA), the European Atherosclerosis Society (EAS), the Italian Society of Endocrinology (SIE), the Italian Society of Diabetology (SID), and the Diabetes Research Institute Federation (DRIF, Rome Chapter), a global alliance of researchers who are focused on the cure research for type 1 diabetes mellitus.
Articles
Books
Editorial Roles
Marco Infante serves as Academic Editor of the international peer-reviewed scientific journal Journal of Diabetes Research (Wiley publisher) and as Associate Editor of the international peer-reviewed scientific journal Frontiers in Clinical Diabetes and Healthcare.
Monographies
“Evolving Concepts in Insulin Resistance” – Academic Editor: Marco Infante (published by IntechOpen in December 2022). This book presents a comprehensive overview of the pathophysiology and clinical consequences of insulin resistance in different settings, describing novel diagnostic biomarkers and molecular targets of this common condition.